Something else that hasn't been mentioned is the significant cost of running trials. Halving the patients will be a massive expenditure not needeed. While highly unlikely to halve the cost, it could potentially save us a quarter or even a third of the original forecast expense as compared to what it would have cost a week ago. I think our q4 books are going to look pretty good.
Something else that hasn't been mentioned is the significant...
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.1¢ |
Change
0.001(0.71%) |
Mkt cap ! $512.3M | |||
| Open | High | Low | Value | Volume |
| 7.0¢ | 7.1¢ | 7.0¢ | $257.0K | 3.667M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 293778 | 7.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.1¢ | 1974877 | 21 |
View Market Depth
| Last trade - 10.58am 27/05/2024 (20 minute delay) ? |
|
|||||
|
Last
6.9¢ |
Change
0.001 ( 1.71 %) |
||||
| Open | High | Low | Volume | ||
| 7.1¢ | 7.1¢ | 6.9¢ | 2567840 | ||
| Last updated 11.22am 27/05/2024 ? | |||||
| IMU (ASX) Chart |